CY1119967T1 - Αναστολη πρωτεασης - Google Patents

Αναστολη πρωτεασης

Info

Publication number
CY1119967T1
CY1119967T1 CY20181100165T CY181100165T CY1119967T1 CY 1119967 T1 CY1119967 T1 CY 1119967T1 CY 20181100165 T CY20181100165 T CY 20181100165T CY 181100165 T CY181100165 T CY 181100165T CY 1119967 T1 CY1119967 T1 CY 1119967T1
Authority
CY
Cyprus
Prior art keywords
protest
suspension
proteins
genetically engineered
disclosed
Prior art date
Application number
CY20181100165T
Other languages
Greek (el)
English (en)
Inventor
Robert C. Ladner
Original Assignee
Dyax Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dyax Corp. filed Critical Dyax Corp.
Publication of CY1119967T1 publication Critical patent/CY1119967T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81Protease inhibitors
    • C07K14/8107Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114Kunitz type inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CY20181100165T 2005-12-29 2018-02-09 Αναστολη πρωτεασης CY1119967T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75490305P 2005-12-29 2005-12-29
PCT/US2006/049322 WO2007079096A2 (en) 2005-12-29 2006-12-27 Protease inhibition

Publications (1)

Publication Number Publication Date
CY1119967T1 true CY1119967T1 (el) 2018-12-12

Family

ID=38228815

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20181100165T CY1119967T1 (el) 2005-12-29 2018-02-09 Αναστολη πρωτεασης

Country Status (14)

Country Link
US (1) US8828703B2 (https=)
EP (1) EP1981519B1 (https=)
JP (2) JP5632126B2 (https=)
AU (1) AU2006332774A1 (https=)
CA (1) CA2635589C (https=)
CY (1) CY1119967T1 (https=)
DK (1) DK1981519T3 (https=)
ES (1) ES2663497T3 (https=)
HU (1) HUE038243T2 (https=)
LT (1) LT1981519T (https=)
PL (1) PL1981519T3 (https=)
PT (1) PT1981519T (https=)
SI (1) SI1981519T1 (https=)
WO (1) WO2007079096A2 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US20050222023A1 (en) * 2002-02-07 2005-10-06 Hans-Peter Hauser Albumin-fused kunitz domain peptides
WO2003103475A2 (en) 2002-06-07 2003-12-18 Dyax Corp. Prevention and reduction of blood loss
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
JP2005537006A (ja) 2002-08-28 2005-12-08 ダイアックス、コープ 臓器及び組織の保存方法
PT1663281E (pt) * 2003-08-29 2014-03-17 Dyax Corp Inibidores de proteases poli-peguilados
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
US8137929B2 (en) 2005-04-15 2012-03-20 Novo Nordisk Health Care Ag Basic protein purification tags from thermophilic bacteria
JP2010505437A (ja) * 2006-10-13 2010-02-25 ノボ ノルディスク ヘルス ケア アーゲー 塩基性タンパク質タグに融合したプロセシング酵素
CA2696208A1 (en) * 2007-08-21 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
CA2695012A1 (en) * 2007-08-23 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
EP2350305A4 (en) * 2008-10-22 2013-03-06 Dyax Corp COMBINATION TREATMENTS WITH PROTEASE BINDING PROTEINS FOR INFLAMMATORY DISEASES
CA2744235A1 (en) 2009-01-06 2010-07-15 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
EP2405925B1 (en) * 2009-03-10 2015-01-14 Med Discovery Sa Kallikrein inhibitors for the treatment of neutropenia
GB0916578D0 (en) * 2009-09-22 2009-10-28 Malmsten Nils M Polypeptides and uses thereof
EP3459564B1 (en) 2010-01-06 2021-10-27 Takeda Pharmaceutical Company Limited Plasma kallikrein binding proteins
US9597379B1 (en) * 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
CA2823776A1 (en) 2011-01-06 2012-07-12 Dyax Corp. Plasma kallikrein binding proteins
US10314909B2 (en) 2011-10-21 2019-06-11 Dyax Corp. Combination therapy comprising an MMP-14 binding protein
ES2886531T3 (es) 2013-01-07 2021-12-20 Omniox Inc Formas poliméricas de proteínas H-NOX
WO2014113712A1 (en) 2013-01-20 2014-07-24 Dyax Corp. Evaluation and treatment of bradykinin-mediated disorders
JP6757252B2 (ja) 2013-10-21 2020-09-16 ダイアックス コーポレーション 血漿カリクレイン系バイオマーカーを決定するためのアッセイ
CA2927695C (en) * 2013-10-21 2022-03-01 Dyax Corp. Diagnosis and treatment of autoimmune diseases
PL3110434T3 (pl) 2014-02-24 2019-01-31 Takeda Gmbh Białka fuzyjne uti
IL295414B2 (en) 2014-03-27 2026-02-01 Takeda Pharmaceuticals Co Compositions and methods for treating macular edema due to diabetes
CN107580499A (zh) 2015-03-17 2018-01-12 欧姆尼奥克斯公司 通过蛋白质介导的o2递送调节肿瘤免疫性
KR20240133761A (ko) 2015-10-19 2024-09-04 다케다 파머수티컬 컴패니 리미티드 절단된 고분자량 키니노겐의 검출을 위한 면역검정법
AU2016366557B2 (en) 2015-12-11 2024-01-25 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
JP6467073B2 (ja) * 2018-01-04 2019-02-06 オムニオクス, インコーポレイテッド H−noxタンパク質の重合体形態
KR20200143376A (ko) * 2018-03-13 2020-12-23 샤이어 휴먼 지네틱 테라피즈 인크. 혈장 칼리크레인 억제제로서의 치환된 이미다조피리딘 및 이의 용도
MX2022001812A (es) * 2019-08-12 2022-03-11 Regeneron Pharma Variantes del receptor estimulante de macrofagos 1 (mst1r) y sus usos.
CN114667289B (zh) 2019-09-18 2025-08-26 武田药品工业有限公司 杂芳基血浆激肽释放酶抑制剂
EP4031547B1 (en) 2019-09-18 2024-07-17 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof
US12528880B2 (en) 2020-01-13 2026-01-20 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0779702B2 (ja) 1986-11-17 1995-08-30 サイオス ノバ インコーポレイテッド 組換えアルツハイマーアミロイドタンパク
US4966852A (en) 1987-07-23 1990-10-30 Monsanto Company DNA clone of human tissue factor inhibitor
US5106833A (en) 1987-07-23 1992-04-21 Washington University Coagulation inhibitors
IL87172A (en) 1987-07-23 1994-12-29 Univ Washington Method of isolating highly purified tissue factor inhibitor
IL87171A (en) 1987-11-23 1995-08-31 Monsanto Co cDNA of human tissue factor inhibitor
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5663143A (en) 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
US7078383B2 (en) 1988-09-02 2006-07-18 Dyax Corp. ITI-D1 Kunitz domain mutants as HNE inhibitors
DK408089D0 (da) 1989-08-18 1989-08-18 Novo Nordisk As Proteiner
US5378614A (en) 1989-08-18 1995-01-03 Novo Nordisk A/S Vector and method for making tissue factor pathway inhibitor (TFPI) analogues in yeast
IL104314A0 (en) 1992-01-07 1993-05-13 Novo Nordisk As Human kunitz-type protease inhibitor and variants thereof,their production and pharmaceutical compositions containing them
IL104327A0 (en) 1992-01-07 1993-05-13 Novo Nordisk As Variant of human kunitz-type protease inhibitor
US5212091A (en) 1992-03-02 1993-05-18 Monsanto Company Method of producing tissue factor pathway inhibitor
US6063764A (en) 1992-06-01 2000-05-16 Washington University & Chiron Corp. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
US5455338A (en) 1993-11-05 1995-10-03 Zymogenetics, Inc. DNA encoding novel human kunitz-type inhibitors and methods relating thereto
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
PT739355E (pt) 1994-01-11 2005-01-31 Dyax Corp Proteinas de 'dominio de kunitz' inibidoras de calicreina e seus analogos
ES2229236T3 (es) 1994-01-11 2005-04-16 Dyax Corporation Inhibidores de la plasmina humana derivados de los dominios de kunitz.
US5795954A (en) 1994-03-04 1998-08-18 Genentech, Inc. Factor VIIa inhibitors from Kunitz domain proteins
EP0763055B1 (en) 1994-06-02 1999-11-03 Merrell Pharmaceuticals Inc. Perfluoroalkyl ketone inhibitors of elastase and processes for making the same
JP3779728B2 (ja) 1994-08-05 2006-05-31 カイロン コーポレイション 組織因子活性インヒビターの産生
US5589359A (en) 1994-08-05 1996-12-31 Chiron Corporation Chimeric proteins
US5648331A (en) 1994-08-26 1997-07-15 G.D. Searle & Co. Method of inhibiting tissue ischemia and reperfusion injury
US5914316A (en) 1994-12-16 1999-06-22 Washington University Method of inhibiting intimal hyperplasia
ZA963619B (en) 1995-05-08 1996-11-22 Scios Inc Protease inhibitor peptides
US5786328A (en) 1995-06-05 1998-07-28 Genentech, Inc. Use of kunitz type plasma kallikrein inhibitors
US5780265A (en) 1995-06-05 1998-07-14 Genentech, Inc. Kunitz type plasma kallikrein inhibitors
US6242414B1 (en) 1995-06-07 2001-06-05 Chiron Corporation Regulation of cytokine synthesis and release
US5736364A (en) 1995-12-04 1998-04-07 Genentech, Inc. Factor viia inhibitors
IL126115A (en) 1996-03-11 2007-03-08 Aerovance Inc Significantly purified protein with suppressive activity for sirin protease and its pharmaceutical preparations
CA2279345A1 (en) 1997-01-31 1998-08-06 Human Genome Sciences, Inc. Tissue factor pathway inhibitor-3
US6180607B1 (en) 1999-08-05 2001-01-30 Christopher Davies Protein having proteinase inhibitor activity
US6544760B2 (en) 1999-12-22 2003-04-08 Zymogenetics, Inc. Kunitz domain polypeptide Zkun11
US20020102703A1 (en) 1999-12-29 2002-08-01 Sheppard Paul O. Kunitz domain polypeptide zkun10
WO2001068707A1 (en) 2000-03-13 2001-09-20 Eli Lilly And Company Human hepatocyte growth factor activator inhibitor homologue
US20040152633A1 (en) * 2001-05-31 2004-08-05 Jorgensen Marianne Ulrich Kunitz-type sequences and polypeptides
US20030129659A1 (en) 2001-12-03 2003-07-10 Whelihan E. Fayelle Library screening
AU2003244515A1 (en) * 2002-02-07 2003-09-02 Novozymes Delta Limited Albumin-fused anti-angiogenesis peptides
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
US6989369B2 (en) 2003-02-07 2006-01-24 Dyax Corp. Kunitz domain peptides
WO2005019270A2 (en) 2003-08-14 2005-03-03 Dyax Corp. Endotheliase-2 ligands
PT1663281E (pt) 2003-08-29 2014-03-17 Dyax Corp Inibidores de proteases poli-peguilados
WO2005021556A2 (en) 2003-08-29 2005-03-10 Dyax Corp. Modified protease inhibitors
WO2005041631A2 (en) * 2003-10-21 2005-05-12 Dyax Corp. Endotheliase-1 ligands
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
EP1835926A4 (en) 2004-11-22 2009-04-01 Dyax Corp PLASMINE-INHIBITING THERAPIES

Also Published As

Publication number Publication date
ES2663497T3 (es) 2018-04-13
WO2007079096A2 (en) 2007-07-12
US20080255025A1 (en) 2008-10-16
HUE038243T2 (hu) 2018-10-29
JP5632126B2 (ja) 2014-11-26
JP2009521926A (ja) 2009-06-11
EP1981519B1 (en) 2017-12-27
CA2635589C (en) 2017-01-17
US8828703B2 (en) 2014-09-09
PT1981519T (pt) 2018-02-23
JP2012235793A (ja) 2012-12-06
WO2007079096A3 (en) 2008-02-14
EP1981519A2 (en) 2008-10-22
SI1981519T1 (en) 2018-05-31
CA2635589A1 (en) 2007-07-12
DK1981519T3 (en) 2018-02-19
LT1981519T (lt) 2018-04-25
EP1981519A4 (en) 2010-01-06
PL1981519T3 (pl) 2018-07-31
AU2006332774A1 (en) 2007-07-12

Similar Documents

Publication Publication Date Title
CY1119967T1 (el) Αναστολη πρωτεασης
CY1114916T1 (el) Μεθοδοι
ECSP044996A (es) Agentes de contraste de objetivo multimérico basado en péptido
NO20073368L (no) Amid-promedikament av gemcitabin, sammensetninger og anvendelse derav
ATE407967T1 (de) Nukleierungsmittel
DK2046951T3 (da) Proteasesreeningsmetoder og proteaser identificeret dermed
DE602004024107D1 (de) Vektoren zur gerichteten klonierung
NO20044039L (no) Konjugatorer av terapeutiske eller cytotoksiske midler og biologisk aktive peptider.
CY1106640T1 (el) Αναστολεις κρουζιπαϊνης και αλλων πρωτεασων κυστεϊνης
CY1111225T1 (el) Νεα πεπτιδια ως αναστολεις πρωτεασης νs3-σερινης ιου ηπατiτιδας c
CY1109068T1 (el) Υποκατεστημενες πυριδινυλαμινες
EA200701918A1 (ru) Белок липокалин
CY1109741T1 (el) Sns-595 και μεθοδοι χρησης αυτου
ATE424560T1 (de) Marker für neuromyelitis optica
DK1737961T3 (da) Modificerede bouganin proteiner, cytotoxiner og fremgangsmåder og anvendelser deraf
DE60230456D1 (de) Faktor-viii-polypeptide auf hohem expressionsnivea und verwendungsverfahren
EA200701528A1 (ru) Новые нутрицевтические композиции
PA8508301A1 (es) Inhibidores de la proteina c del procolageno
ATE484201T1 (de) Verwendung von beta-cryptoxanthin
ATE532861T1 (de) Expressionsvektor
ATE497506T1 (de) Sars-verwandte proteine
ATE543833T1 (de) Bmp-7-varianten-zusammensetzungen, verfahren und verwendungen
EA200601855A1 (ru) Гербицидоактивные 3-амино-2-тиометилбензоилпиразолы
TW200700089A (en) Recombinant protein comprising starch binding domain and use thereof
NO20053903D0 (no) Nukleotidlipidesterderivater.